http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 23 Jul 2026 13:00:20 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Management+Changes/Tessera+Therapeutics+names+former+Merck+executive+as+new+CEO/26807060.html <p>Tessera Therapeutics has appointed Joseph Romanelli as President and Chief Executive Officer, succeeding Michael Severino, who has led the company since June 2022, according to a press release.</p> <p>Romanelli joins from Merck & Co., Inc. (NYSE: MRK), where he most recently served as President of Human Health International and a member of the company's Executive Team, overseeing a business of more than $25 billion across 75 markets outside the United States. During his nearly 30-year career at Merck, he also led the company's China operations from 2016 through 2021. Romanelli will join Tessera's board of directors and will also join Flagship http://www.streetinsider.com/Management+Changes/Tessera+Therapeutics+names+former+Merck+executive+as+new+CEO/26807060.html Thu, 23 Jul 2026 13:00:20 -0400 A.02797610 A.06145069 A.19652380 A.50213909 MRK O.00037438 O.00096048 O.20061049 O.20357061 O.30003192 O.31241813 REGN http://www.streetinsider.com/Management+Changes/Tessera+Therapeutics+names+former+Merck+executive+as+new+CEO/26807060.html <p>Tessera Therapeutics has appointed Joseph Romanelli as President and Chief Executive Officer, succeeding Michael Severino, who has led the company since June 2022, according to a press release.</p> <p>Romanelli joins from Merck & Co., Inc. (NYSE: MRK), where he most recently served as President of Human Health International and a member of the company's Executive Team, overseeing a business of more than $25 billion across 75 markets outside the United States. During his nearly 30-year career at Merck, he also led the company's China operations from 2016 through 2021. Romanelli will join Tessera's board of directors and will also join Flagship http://www.streetinsider.com/Management+Changes/Tessera+Therapeutics+names+former+Merck+executive+as+new+CEO/26807060.html Thu, 23 Jul 2026 13:00:20 -0400 A.02797610 A.06145069 A.19652380 A.50213909 MRK O.00037438 O.00096048 O.20061049 O.20357061 O.30003192 O.31241813 REGN http://www.streetinsider.com/Management+Changes/Tessera+Therapeutics+names+former+Merck+executive+as+new+CEO/26807060.html <p>Tessera Therapeutics has appointed Joseph Romanelli as President and Chief Executive Officer, succeeding Michael Severino, who has led the company since June 2022, according to a press release.</p> <p>Romanelli joins from Merck & Co., Inc. (NYSE: MRK), where he most recently served as President of Human Health International and a member of the company's Executive Team, overseeing a business of more than $25 billion across 75 markets outside the United States. During his nearly 30-year career at Merck, he also led the company's China operations from 2016 through 2021. Romanelli will join Tessera's board of directors and will also join Flagship http://www.streetinsider.com/Management+Changes/Tessera+Therapeutics+names+former+Merck+executive+as+new+CEO/26807060.html Thu, 23 Jul 2026 13:00:20 -0400 A.02797610 A.06145069 A.19652380 A.50213909 MRK O.00037438 O.00096048 O.20061049 O.20357061 O.30003192 O.31241813 REGN http://www.streetinsider.com/Management+Changes/Tessera+Therapeutics+names+former+Merck+executive+as+new+CEO/26807060.html <p>Tessera Therapeutics has appointed Joseph Romanelli as President and Chief Executive Officer, succeeding Michael Severino, who has led the company since June 2022, according to a press release.</p> <p>Romanelli joins from Merck & Co., Inc. (NYSE: MRK), where he most recently served as President of Human Health International and a member of the company's Executive Team, overseeing a business of more than $25 billion across 75 markets outside the United States. During his nearly 30-year career at Merck, he also led the company's China operations from 2016 through 2021. Romanelli will join Tessera's board of directors and will also join Flagship http://www.streetinsider.com/Management+Changes/Tessera+Therapeutics+names+former+Merck+executive+as+new+CEO/26807060.html Thu, 23 Jul 2026 13:00:20 -0400 A.02797610 A.06145069 A.19652380 A.50213909 MRK O.00037438 O.00096048 O.20061049 O.20357061 O.30003192 O.31241813 REGN http://www.streetinsider.com/Management+Changes/Tessera+Therapeutics+names+former+Merck+executive+as+new+CEO/26807060.html <p>Tessera Therapeutics has appointed Joseph Romanelli as President and Chief Executive Officer, succeeding Michael Severino, who has led the company since June 2022, according to a press release.</p> <p>Romanelli joins from Merck & Co., Inc. (NYSE: MRK), where he most recently served as President of Human Health International and a member of the company's Executive Team, overseeing a business of more than $25 billion across 75 markets outside the United States. During his nearly 30-year career at Merck, he also led the company's China operations from 2016 through 2021. Romanelli will join Tessera's board of directors and will also join Flagship http://www.streetinsider.com/Management+Changes/Tessera+Therapeutics+names+former+Merck+executive+as+new+CEO/26807060.html Thu, 23 Jul 2026 13:00:20 -0400 A.02797610 A.06145069 A.19652380 A.50213909 MRK O.00037438 O.00096048 O.20061049 O.20357061 O.30003192 O.31241813 REGN http://www.streetinsider.com/Management+Changes/Tessera+Therapeutics+names+former+Merck+executive+as+new+CEO/26807060.html <p>Tessera Therapeutics has appointed Joseph Romanelli as President and Chief Executive Officer, succeeding Michael Severino, who has led the company since June 2022, according to a press release.</p> <p>Romanelli joins from Merck & Co., Inc. (NYSE: MRK), where he most recently served as President of Human Health International and a member of the company's Executive Team, overseeing a business of more than $25 billion across 75 markets outside the United States. During his nearly 30-year career at Merck, he also led the company's China operations from 2016 through 2021. Romanelli will join Tessera's board of directors and will also join Flagship http://www.streetinsider.com/Management+Changes/Tessera+Therapeutics+names+former+Merck+executive+as+new+CEO/26807060.html Thu, 23 Jul 2026 13:00:20 -0400 A.02797610 A.06145069 A.19652380 A.50213909 MRK O.00037438 O.00096048 O.20061049 O.20357061 O.30003192 O.31241813 REGN http://www.streetinsider.com/Management+Changes/Tessera+Therapeutics+names+former+Merck+executive+as+new+CEO/26807060.html <p>Tessera Therapeutics has appointed Joseph Romanelli as President and Chief Executive Officer, succeeding Michael Severino, who has led the company since June 2022, according to a press release.</p> <p>Romanelli joins from Merck & Co., Inc. (NYSE: MRK), where he most recently served as President of Human Health International and a member of the company's Executive Team, overseeing a business of more than $25 billion across 75 markets outside the United States. During his nearly 30-year career at Merck, he also led the company's China operations from 2016 through 2021. Romanelli will join Tessera's board of directors and will also join Flagship http://www.streetinsider.com/Management+Changes/Tessera+Therapeutics+names+former+Merck+executive+as+new+CEO/26807060.html Thu, 23 Jul 2026 13:00:20 -0400 A.02797610 A.06145069 A.19652380 A.50213909 MRK O.00037438 O.00096048 O.20061049 O.20357061 O.30003192 O.31241813 REGN http://www.streetinsider.com/Management+Changes/Tessera+Therapeutics+names+former+Merck+executive+as+new+CEO/26807060.html <p>Tessera Therapeutics has appointed Joseph Romanelli as President and Chief Executive Officer, succeeding Michael Severino, who has led the company since June 2022, according to a press release.</p> <p>Romanelli joins from Merck & Co., Inc. (NYSE: MRK), where he most recently served as President of Human Health International and a member of the company's Executive Team, overseeing a business of more than $25 billion across 75 markets outside the United States. During his nearly 30-year career at Merck, he also led the company's China operations from 2016 through 2021. Romanelli will join Tessera's board of directors and will also join Flagship http://www.streetinsider.com/Management+Changes/Tessera+Therapeutics+names+former+Merck+executive+as+new+CEO/26807060.html Thu, 23 Jul 2026 13:00:20 -0400 A.02797610 A.06145069 A.19652380 A.50213909 MRK O.00037438 O.00096048 O.20061049 O.20357061 O.30003192 O.31241813 REGN http://www.streetinsider.com/Management+Changes/Tessera+Therapeutics+names+former+Merck+executive+as+new+CEO/26807060.html <p>Tessera Therapeutics has appointed Joseph Romanelli as President and Chief Executive Officer, succeeding Michael Severino, who has led the company since June 2022, according to a press release.</p> <p>Romanelli joins from Merck & Co., Inc. (NYSE: MRK), where he most recently served as President of Human Health International and a member of the company's Executive Team, overseeing a business of more than $25 billion across 75 markets outside the United States. During his nearly 30-year career at Merck, he also led the company's China operations from 2016 through 2021. Romanelli will join Tessera's board of directors and will also join Flagship http://www.streetinsider.com/Management+Changes/Tessera+Therapeutics+names+former+Merck+executive+as+new+CEO/26807060.html Thu, 23 Jul 2026 13:00:20 -0400 A.02797610 A.06145069 A.19652380 A.50213909 MRK O.00037438 O.00096048 O.20061049 O.20357061 O.30003192 O.31241813 REGN http://www.streetinsider.com/Management+Changes/Tessera+Therapeutics+names+former+Merck+executive+as+new+CEO/26807060.html <p>Tessera Therapeutics has appointed Joseph Romanelli as President and Chief Executive Officer, succeeding Michael Severino, who has led the company since June 2022, according to a press release.</p> <p>Romanelli joins from Merck & Co., Inc. (NYSE: MRK), where he most recently served as President of Human Health International and a member of the company's Executive Team, overseeing a business of more than $25 billion across 75 markets outside the United States. During his nearly 30-year career at Merck, he also led the company's China operations from 2016 through 2021. Romanelli will join Tessera's board of directors and will also join Flagship http://www.streetinsider.com/Management+Changes/Tessera+Therapeutics+names+former+Merck+executive+as+new+CEO/26807060.html Thu, 23 Jul 2026 13:00:20 -0400 A.02797610 A.06145069 A.19652380 A.50213909 MRK O.00037438 O.00096048 O.20061049 O.20357061 O.30003192 O.31241813 REGN http://www.streetinsider.com/Management+Changes/Tessera+Therapeutics+names+former+Merck+executive+as+new+CEO/26807060.html <p>Tessera Therapeutics has appointed Joseph Romanelli as President and Chief Executive Officer, succeeding Michael Severino, who has led the company since June 2022, according to a press release.</p> <p>Romanelli joins from Merck & Co., Inc. (NYSE: MRK), where he most recently served as President of Human Health International and a member of the company's Executive Team, overseeing a business of more than $25 billion across 75 markets outside the United States. During his nearly 30-year career at Merck, he also led the company's China operations from 2016 through 2021. Romanelli will join Tessera's board of directors and will also join Flagship http://www.streetinsider.com/Management+Changes/Tessera+Therapeutics+names+former+Merck+executive+as+new+CEO/26807060.html Thu, 23 Jul 2026 13:00:20 -0400 A.02797610 A.06145069 A.19652380 A.50213909 MRK O.00037438 O.00096048 O.20061049 O.20357061 O.30003192 O.31241813 REGN http://www.streetinsider.com/Management+Changes/Tessera+Therapeutics+names+former+Merck+executive+as+new+CEO/26807060.html <p>Tessera Therapeutics has appointed Joseph Romanelli as President and Chief Executive Officer, succeeding Michael Severino, who has led the company since June 2022, according to a press release.</p> <p>Romanelli joins from Merck & Co., Inc. (NYSE: MRK), where he most recently served as President of Human Health International and a member of the company's Executive Team, overseeing a business of more than $25 billion across 75 markets outside the United States. During his nearly 30-year career at Merck, he also led the company's China operations from 2016 through 2021. Romanelli will join Tessera's board of directors and will also join Flagship http://www.streetinsider.com/Management+Changes/Tessera+Therapeutics+names+former+Merck+executive+as+new+CEO/26807060.html Thu, 23 Jul 2026 13:00:20 -0400 A.02797610 A.06145069 A.19652380 A.50213909 MRK O.00037438 O.00096048 O.20061049 O.20357061 O.30003192 O.31241813 REGN http://www.streetinsider.com/Press+Releases/Tessera+Therapeutics+Appoints+Joseph+Romanelli+as+President+and+Chief+Executive+Officer/26807053.html <div class="xn-content"> <p class="prntac"><i>Veteran pharmaceutical executive to lead Tessera's next phase of growth as the company advances Gene Writing from platform innovation toward a broad clinical pipeline of genetic medicines</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.somlle" idsrc="xmltag.org" >SOMERVILLE, Mass.</location></span>, <span class="legendSpanClass"><chron>July 23, 2026</chron></span> /PRNewswire/ -- Tessera Therapeutics ("Tessera"), the biotechnology company pioneering a new approach to genetic medicine known as Gene Writing™, today announced the appointment of <person>Joseph Romanelli</person> as President and Chief Executive Officer. Romanelli succeeds <person>Michael Severino</person> who has led the company since <chron>June 2022</chron>. Romanelli will join Tessera's board of directors and also join Tessera's founder, <span value="ACORN:0614506940" idsrc="xmltag.org" >Flagship Pioneering</span>, as http://www.streetinsider.com/Press+Releases/Tessera+Therapeutics+Appoints+Joseph+Romanelli+as+President+and+Chief+Executive+Officer/26807053.html Thu, 23 Jul 2026 13:00:00 -0400 A.02797610 A.06145069 A.19652380 A.50213909 MRK O.00037438 O.00096048 O.20061049 O.20357061 O.30003192 O.31241813 REGN http://www.streetinsider.com/Press+Releases/Tessera+Therapeutics+Appoints+Joseph+Romanelli+as+President+and+Chief+Executive+Officer/26807053.html <div class="xn-content"> <p class="prntac"><i>Veteran pharmaceutical executive to lead Tessera's next phase of growth as the company advances Gene Writing from platform innovation toward a broad clinical pipeline of genetic medicines</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.somlle" idsrc="xmltag.org" >SOMERVILLE, Mass.</location></span>, <span class="legendSpanClass"><chron>July 23, 2026</chron></span> /PRNewswire/ -- Tessera Therapeutics ("Tessera"), the biotechnology company pioneering a new approach to genetic medicine known as Gene Writing™, today announced the appointment of <person>Joseph Romanelli</person> as President and Chief Executive Officer. Romanelli succeeds <person>Michael Severino</person> who has led the company since <chron>June 2022</chron>. Romanelli will join Tessera's board of directors and also join Tessera's founder, <span value="ACORN:0614506940" idsrc="xmltag.org" >Flagship Pioneering</span>, as http://www.streetinsider.com/Press+Releases/Tessera+Therapeutics+Appoints+Joseph+Romanelli+as+President+and+Chief+Executive+Officer/26807053.html Thu, 23 Jul 2026 13:00:00 -0400 A.02797610 A.06145069 A.19652380 A.50213909 MRK O.00037438 O.00096048 O.20061049 O.20357061 O.30003192 O.31241813 REGN http://www.streetinsider.com/Press+Releases/Tessera+Therapeutics+Appoints+Joseph+Romanelli+as+President+and+Chief+Executive+Officer/26807053.html <div class="xn-content"> <p class="prntac"><i>Veteran pharmaceutical executive to lead Tessera's next phase of growth as the company advances Gene Writing from platform innovation toward a broad clinical pipeline of genetic medicines</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.somlle" idsrc="xmltag.org" >SOMERVILLE, Mass.</location></span>, <span class="legendSpanClass"><chron>July 23, 2026</chron></span> /PRNewswire/ -- Tessera Therapeutics ("Tessera"), the biotechnology company pioneering a new approach to genetic medicine known as Gene Writing™, today announced the appointment of <person>Joseph Romanelli</person> as President and Chief Executive Officer. Romanelli succeeds <person>Michael Severino</person> who has led the company since <chron>June 2022</chron>. Romanelli will join Tessera's board of directors and also join Tessera's founder, <span value="ACORN:0614506940" idsrc="xmltag.org" >Flagship Pioneering</span>, as http://www.streetinsider.com/Press+Releases/Tessera+Therapeutics+Appoints+Joseph+Romanelli+as+President+and+Chief+Executive+Officer/26807053.html Thu, 23 Jul 2026 13:00:00 -0400 A.02797610 A.06145069 A.19652380 A.50213909 MRK O.00037438 O.00096048 O.20061049 O.20357061 O.30003192 O.31241813 REGN http://www.streetinsider.com/Press+Releases/Tessera+Therapeutics+Appoints+Joseph+Romanelli+as+President+and+Chief+Executive+Officer/26807053.html <div class="xn-content"> <p class="prntac"><i>Veteran pharmaceutical executive to lead Tessera's next phase of growth as the company advances Gene Writing from platform innovation toward a broad clinical pipeline of genetic medicines</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.somlle" idsrc="xmltag.org" >SOMERVILLE, Mass.</location></span>, <span class="legendSpanClass"><chron>July 23, 2026</chron></span> /PRNewswire/ -- Tessera Therapeutics ("Tessera"), the biotechnology company pioneering a new approach to genetic medicine known as Gene Writing™, today announced the appointment of <person>Joseph Romanelli</person> as President and Chief Executive Officer. Romanelli succeeds <person>Michael Severino</person> who has led the company since <chron>June 2022</chron>. Romanelli will join Tessera's board of directors and also join Tessera's founder, <span value="ACORN:0614506940" idsrc="xmltag.org" >Flagship Pioneering</span>, as http://www.streetinsider.com/Press+Releases/Tessera+Therapeutics+Appoints+Joseph+Romanelli+as+President+and+Chief+Executive+Officer/26807053.html Thu, 23 Jul 2026 13:00:00 -0400 A.02797610 A.06145069 A.19652380 A.50213909 MRK O.00037438 O.00096048 O.20061049 O.20357061 O.30003192 O.31241813 REGN http://www.streetinsider.com/Press+Releases/Tessera+Therapeutics+Appoints+Joseph+Romanelli+as+President+and+Chief+Executive+Officer/26807053.html <div class="xn-content"> <p class="prntac"><i>Veteran pharmaceutical executive to lead Tessera's next phase of growth as the company advances Gene Writing from platform innovation toward a broad clinical pipeline of genetic medicines</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.somlle" idsrc="xmltag.org" >SOMERVILLE, Mass.</location></span>, <span class="legendSpanClass"><chron>July 23, 2026</chron></span> /PRNewswire/ -- Tessera Therapeutics ("Tessera"), the biotechnology company pioneering a new approach to genetic medicine known as Gene Writing™, today announced the appointment of <person>Joseph Romanelli</person> as President and Chief Executive Officer. Romanelli succeeds <person>Michael Severino</person> who has led the company since <chron>June 2022</chron>. Romanelli will join Tessera's board of directors and also join Tessera's founder, <span value="ACORN:0614506940" idsrc="xmltag.org" >Flagship Pioneering</span>, as http://www.streetinsider.com/Press+Releases/Tessera+Therapeutics+Appoints+Joseph+Romanelli+as+President+and+Chief+Executive+Officer/26807053.html Thu, 23 Jul 2026 13:00:00 -0400 A.02797610 A.06145069 A.19652380 A.50213909 MRK O.00037438 O.00096048 O.20061049 O.20357061 O.30003192 O.31241813 REGN http://www.streetinsider.com/Press+Releases/Tessera+Therapeutics+Appoints+Joseph+Romanelli+as+President+and+Chief+Executive+Officer/26807053.html <div class="xn-content"> <p class="prntac"><i>Veteran pharmaceutical executive to lead Tessera's next phase of growth as the company advances Gene Writing from platform innovation toward a broad clinical pipeline of genetic medicines</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.somlle" idsrc="xmltag.org" >SOMERVILLE, Mass.</location></span>, <span class="legendSpanClass"><chron>July 23, 2026</chron></span> /PRNewswire/ -- Tessera Therapeutics ("Tessera"), the biotechnology company pioneering a new approach to genetic medicine known as Gene Writing™, today announced the appointment of <person>Joseph Romanelli</person> as President and Chief Executive Officer. Romanelli succeeds <person>Michael Severino</person> who has led the company since <chron>June 2022</chron>. Romanelli will join Tessera's board of directors and also join Tessera's founder, <span value="ACORN:0614506940" idsrc="xmltag.org" >Flagship Pioneering</span>, as http://www.streetinsider.com/Press+Releases/Tessera+Therapeutics+Appoints+Joseph+Romanelli+as+President+and+Chief+Executive+Officer/26807053.html Thu, 23 Jul 2026 13:00:00 -0400 A.02797610 A.06145069 A.19652380 A.50213909 MRK O.00037438 O.00096048 O.20061049 O.20357061 O.30003192 O.31241813 REGN http://www.streetinsider.com/Press+Releases/Tessera+Therapeutics+Appoints+Joseph+Romanelli+as+President+and+Chief+Executive+Officer/26807053.html <div class="xn-content"> <p class="prntac"><i>Veteran pharmaceutical executive to lead Tessera's next phase of growth as the company advances Gene Writing from platform innovation toward a broad clinical pipeline of genetic medicines</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.somlle" idsrc="xmltag.org" >SOMERVILLE, Mass.</location></span>, <span class="legendSpanClass"><chron>July 23, 2026</chron></span> /PRNewswire/ -- Tessera Therapeutics ("Tessera"), the biotechnology company pioneering a new approach to genetic medicine known as Gene Writing™, today announced the appointment of <person>Joseph Romanelli</person> as President and Chief Executive Officer. Romanelli succeeds <person>Michael Severino</person> who has led the company since <chron>June 2022</chron>. Romanelli will join Tessera's board of directors and also join Tessera's founder, <span value="ACORN:0614506940" idsrc="xmltag.org" >Flagship Pioneering</span>, as http://www.streetinsider.com/Press+Releases/Tessera+Therapeutics+Appoints+Joseph+Romanelli+as+President+and+Chief+Executive+Officer/26807053.html Thu, 23 Jul 2026 13:00:00 -0400 A.02797610 A.06145069 A.19652380 A.50213909 MRK O.00037438 O.00096048 O.20061049 O.20357061 O.30003192 O.31241813 REGN http://www.streetinsider.com/Press+Releases/Tessera+Therapeutics+Appoints+Joseph+Romanelli+as+President+and+Chief+Executive+Officer/26807053.html <div class="xn-content"> <p class="prntac"><i>Veteran pharmaceutical executive to lead Tessera's next phase of growth as the company advances Gene Writing from platform innovation toward a broad clinical pipeline of genetic medicines</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.somlle" idsrc="xmltag.org" >SOMERVILLE, Mass.</location></span>, <span class="legendSpanClass"><chron>July 23, 2026</chron></span> /PRNewswire/ -- Tessera Therapeutics ("Tessera"), the biotechnology company pioneering a new approach to genetic medicine known as Gene Writing™, today announced the appointment of <person>Joseph Romanelli</person> as President and Chief Executive Officer. Romanelli succeeds <person>Michael Severino</person> who has led the company since <chron>June 2022</chron>. Romanelli will join Tessera's board of directors and also join Tessera's founder, <span value="ACORN:0614506940" idsrc="xmltag.org" >Flagship Pioneering</span>, as http://www.streetinsider.com/Press+Releases/Tessera+Therapeutics+Appoints+Joseph+Romanelli+as+President+and+Chief+Executive+Officer/26807053.html Thu, 23 Jul 2026 13:00:00 -0400 A.02797610 A.06145069 A.19652380 A.50213909 MRK O.00037438 O.00096048 O.20061049 O.20357061 O.30003192 O.31241813 REGN http://www.streetinsider.com/Press+Releases/Tessera+Therapeutics+Appoints+Joseph+Romanelli+as+President+and+Chief+Executive+Officer/26807053.html <div class="xn-content"> <p class="prntac"><i>Veteran pharmaceutical executive to lead Tessera's next phase of growth as the company advances Gene Writing from platform innovation toward a broad clinical pipeline of genetic medicines</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.somlle" idsrc="xmltag.org" >SOMERVILLE, Mass.</location></span>, <span class="legendSpanClass"><chron>July 23, 2026</chron></span> /PRNewswire/ -- Tessera Therapeutics ("Tessera"), the biotechnology company pioneering a new approach to genetic medicine known as Gene Writing™, today announced the appointment of <person>Joseph Romanelli</person> as President and Chief Executive Officer. Romanelli succeeds <person>Michael Severino</person> who has led the company since <chron>June 2022</chron>. Romanelli will join Tessera's board of directors and also join Tessera's founder, <span value="ACORN:0614506940" idsrc="xmltag.org" >Flagship Pioneering</span>, as http://www.streetinsider.com/Press+Releases/Tessera+Therapeutics+Appoints+Joseph+Romanelli+as+President+and+Chief+Executive+Officer/26807053.html Thu, 23 Jul 2026 13:00:00 -0400 A.02797610 A.06145069 A.19652380 A.50213909 MRK O.00037438 O.00096048 O.20061049 O.20357061 O.30003192 O.31241813 REGN http://www.streetinsider.com/Press+Releases/Tessera+Therapeutics+Appoints+Joseph+Romanelli+as+President+and+Chief+Executive+Officer/26807053.html <div class="xn-content"> <p class="prntac"><i>Veteran pharmaceutical executive to lead Tessera's next phase of growth as the company advances Gene Writing from platform innovation toward a broad clinical pipeline of genetic medicines</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.somlle" idsrc="xmltag.org" >SOMERVILLE, Mass.</location></span>, <span class="legendSpanClass"><chron>July 23, 2026</chron></span> /PRNewswire/ -- Tessera Therapeutics ("Tessera"), the biotechnology company pioneering a new approach to genetic medicine known as Gene Writing™, today announced the appointment of <person>Joseph Romanelli</person> as President and Chief Executive Officer. Romanelli succeeds <person>Michael Severino</person> who has led the company since <chron>June 2022</chron>. Romanelli will join Tessera's board of directors and also join Tessera's founder, <span value="ACORN:0614506940" idsrc="xmltag.org" >Flagship Pioneering</span>, as http://www.streetinsider.com/Press+Releases/Tessera+Therapeutics+Appoints+Joseph+Romanelli+as+President+and+Chief+Executive+Officer/26807053.html Thu, 23 Jul 2026 13:00:00 -0400 A.02797610 A.06145069 A.19652380 A.50213909 MRK O.00037438 O.00096048 O.20061049 O.20357061 O.30003192 O.31241813 REGN http://www.streetinsider.com/Press+Releases/Tessera+Therapeutics+Appoints+Joseph+Romanelli+as+President+and+Chief+Executive+Officer/26807053.html <div class="xn-content"> <p class="prntac"><i>Veteran pharmaceutical executive to lead Tessera's next phase of growth as the company advances Gene Writing from platform innovation toward a broad clinical pipeline of genetic medicines</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.somlle" idsrc="xmltag.org" >SOMERVILLE, Mass.</location></span>, <span class="legendSpanClass"><chron>July 23, 2026</chron></span> /PRNewswire/ -- Tessera Therapeutics ("Tessera"), the biotechnology company pioneering a new approach to genetic medicine known as Gene Writing™, today announced the appointment of <person>Joseph Romanelli</person> as President and Chief Executive Officer. Romanelli succeeds <person>Michael Severino</person> who has led the company since <chron>June 2022</chron>. Romanelli will join Tessera's board of directors and also join Tessera's founder, <span value="ACORN:0614506940" idsrc="xmltag.org" >Flagship Pioneering</span>, as http://www.streetinsider.com/Press+Releases/Tessera+Therapeutics+Appoints+Joseph+Romanelli+as+President+and+Chief+Executive+Officer/26807053.html Thu, 23 Jul 2026 13:00:00 -0400 A.02797610 A.06145069 A.19652380 A.50213909 MRK O.00037438 O.00096048 O.20061049 O.20357061 O.30003192 O.31241813 REGN http://www.streetinsider.com/Press+Releases/Tessera+Therapeutics+Appoints+Joseph+Romanelli+as+President+and+Chief+Executive+Officer/26807053.html <div class="xn-content"> <p class="prntac"><i>Veteran pharmaceutical executive to lead Tessera's next phase of growth as the company advances Gene Writing from platform innovation toward a broad clinical pipeline of genetic medicines</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.somlle" idsrc="xmltag.org" >SOMERVILLE, Mass.</location></span>, <span class="legendSpanClass"><chron>July 23, 2026</chron></span> /PRNewswire/ -- Tessera Therapeutics ("Tessera"), the biotechnology company pioneering a new approach to genetic medicine known as Gene Writing™, today announced the appointment of <person>Joseph Romanelli</person> as President and Chief Executive Officer. Romanelli succeeds <person>Michael Severino</person> who has led the company since <chron>June 2022</chron>. Romanelli will join Tessera's board of directors and also join Tessera's founder, <span value="ACORN:0614506940" idsrc="xmltag.org" >Flagship Pioneering</span>, as http://www.streetinsider.com/Press+Releases/Tessera+Therapeutics+Appoints+Joseph+Romanelli+as+President+and+Chief+Executive+Officer/26807053.html Thu, 23 Jul 2026 13:00:00 -0400 A.02797610 A.06145069 A.19652380 A.50213909 MRK O.00037438 O.00096048 O.20061049 O.20357061 O.30003192 O.31241813 REGN http://www.streetinsider.com/PRNewswire/Tessera+Therapeutics+Appoints+Joseph+Romanelli+as+President+and+Chief+Executive+Officer/26807053.html <div class="xn-content"> <p class="prntac"><i>Veteran pharmaceutical executive to lead Tessera's next phase of growth as the company advances Gene Writing from platform innovation toward a broad clinical pipeline of genetic medicines</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.somlle" idsrc="xmltag.org" >SOMERVILLE, Mass.</location></span>, <span class="legendSpanClass"><chron>July 23, 2026</chron></span> /PRNewswire/ -- Tessera Therapeutics ("Tessera"), the biotechnology company pioneering a new approach to genetic medicine known as Gene Writing™, today announced the appointment of <person>Joseph Romanelli</person> as President and Chief Executive Officer. Romanelli succeeds <person>Michael Severino</person> who has led the company since <chron>June 2022</chron>. Romanelli will join Tessera's board of directors and also join Tessera's founder, <span value="ACORN:0614506940" idsrc="xmltag.org" >Flagship Pioneering</span>, as http://www.streetinsider.com/PRNewswire/Tessera+Therapeutics+Appoints+Joseph+Romanelli+as+President+and+Chief+Executive+Officer/26807053.html Thu, 23 Jul 2026 13:00:00 -0400 A.02797610 A.06145069 A.19652380 A.50213909 MRK O.00037438 O.00096048 O.20061049 O.20357061 O.30003192 O.31241813 REGN